Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin B Kim

Showing results (61-70 of 134) with videos related to

Pageof 14
Sort By:
Thyroid : Official Journal of the American Thyroid Association|March 16, 2013
Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutationKevin B Kim, Maria E Cabanillas, Alexander J Lazar, et al.
Melanoma Research|December 21, 2010
Pelvic computed tomography scans for surveillance in patients with primary melanoma in the head and neckGladys C Alvarado, Nicholas E Papadopoulos, Wen-Jen Hwu, et al.
The Journal of Investigative Dermatology|April 6, 2024
The Molecular Evolution of Melanoma Distant MetastasesVladimir Bezrookove, Sara Kianian, Lea McGeever, et al.
Cancer Epidemiology|October 23, 2018
Association between melanoma and renal-cell carcinoma for sequential diagnoses: A single-center retrospective studyKunhwa Kim, Tong Han Chung, Carol J Etzel, et al.
Cancer Chemotherapy and Pharmacology|November 13, 2008
Phase I study of the combination of docetaxel, temozolomide and cisplatin in patients with metastatic melanomaKevin B Kim, Wen-Jen Hwu, Nicholas E Papadopoulos, et al.
Cancer|August 8, 2013
Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanomaAmanda D Bucheit, Erica Syklawer, John A Jakob, et al.
Scientific Reports|February 10, 2024
ARID2 mutations may relay a distinct subset of cutaneous melanoma patients with different outcomesFavour A Akinjiyan, George Nassief, Jordan Phillipps, et al.
The American Journal of Dermatopathology|June 21, 2014
Histological features associated with vemurafenib-induced skin toxicities: examination of 141 cutaneous lesions biopsied during therapyJonathan L Curry, Michael T Tetzlaff, Kimberly Nicholson, et al.
European Journal of Cancer (Oxford, England : 1990)|September 15, 2015
Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumabZeynep Eroglu, Dae Won Kim, Xiaoyan Wang, et al.
JCO Precision Oncology|May 15, 2025
Phase II Study of Niraparib in Patients With Advanced Melanoma With Homologous Recombination Pathway Gene MutationsKevin B Kim, Pierre-Yves Desprez, David de Semir, et al.
Pageof 14

Showing results (61-70 of 134) with videos related to

Sort By:
Pageof 14
Thyroid : Official Journal of the American Thyroid Association|March 16, 2013
Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutationKevin B Kim, Maria E Cabanillas, Alexander J Lazar, et al.
Melanoma Research|December 21, 2010
Pelvic computed tomography scans for surveillance in patients with primary melanoma in the head and neckGladys C Alvarado, Nicholas E Papadopoulos, Wen-Jen Hwu, et al.
The Journal of Investigative Dermatology|April 6, 2024
The Molecular Evolution of Melanoma Distant MetastasesVladimir Bezrookove, Sara Kianian, Lea McGeever, et al.
Cancer Epidemiology|October 23, 2018
Association between melanoma and renal-cell carcinoma for sequential diagnoses: A single-center retrospective studyKunhwa Kim, Tong Han Chung, Carol J Etzel, et al.
Cancer Chemotherapy and Pharmacology|November 13, 2008
Phase I study of the combination of docetaxel, temozolomide and cisplatin in patients with metastatic melanomaKevin B Kim, Wen-Jen Hwu, Nicholas E Papadopoulos, et al.
Cancer|August 8, 2013
Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanomaAmanda D Bucheit, Erica Syklawer, John A Jakob, et al.
Scientific Reports|February 10, 2024
ARID2 mutations may relay a distinct subset of cutaneous melanoma patients with different outcomesFavour A Akinjiyan, George Nassief, Jordan Phillipps, et al.
The American Journal of Dermatopathology|June 21, 2014
Histological features associated with vemurafenib-induced skin toxicities: examination of 141 cutaneous lesions biopsied during therapyJonathan L Curry, Michael T Tetzlaff, Kimberly Nicholson, et al.
European Journal of Cancer (Oxford, England : 1990)|September 15, 2015
Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumabZeynep Eroglu, Dae Won Kim, Xiaoyan Wang, et al.
JCO Precision Oncology|May 15, 2025
Phase II Study of Niraparib in Patients With Advanced Melanoma With Homologous Recombination Pathway Gene MutationsKevin B Kim, Pierre-Yves Desprez, David de Semir, et al.
Pageof 14